常山药业 reported revenue of ¥0.48B for the period ended 2026-06-30, -3.2% year on year. Net income was ¥-0.02B, a -4.6% net margin on a 21.6% gross margin. The largest revenue line is 水针制剂 at 58% of the total. Free cash flow for the period was ¥-0.04B.
| Item | Amount | Y/Y |
|---|---|---|
| Revenue | ¥0.48B | -3.2% |
| Gross profit | ¥0.10B | — |
| Operating income | ¥-0.02B | — |
| Net income | ¥-0.02B | — |
| Gross margin | 21.6% | Net margin -4.6% |
| Revenue Q/Q | -14.2% | — |
| Segment | Revenue | Share |
|---|---|---|
| 水针制剂 | ¥0.27B | 57.5% |
| 肝素原料药 | ¥0.14B | 30.1% |
| 其他 | ¥0.06B | 12.4% |
| Item | Amount | % of revenue |
|---|---|---|
| Cost of revenue | ¥0.37B | 78.4% |
| R&D | ¥0.02B | 3.3% |
| SG&A | ¥0.06B | 12.9% |
| Tax & other | ¥0.00B | 0.4% |
| Item | Amount |
|---|---|
| Total assets | ¥4.49B |
| Total liabilities | ¥3.34B |
| Shareholders' equity | ¥1.15B |
| Equity / assets | 25.5% |
| Operating cash flow | ¥0.00B |
| Capital expenditure | ¥0.04B |
| Free cash flow | ¥-0.04B |
| Cash conversion (OCF / net income) | -95% |
The Sankey chart shows how revenue splits into cost of revenue, R&D and SG&A, and what remains as profit — clean visuals for research decks and social posts.
星星科技 ・ 开山股份 ・ 精锻科技 ・ 新天科技 ・ 新莱应材 ・ 雅本化学 ・ 隆华科技 ・ 佳创视讯 ・ 通光线缆 ・ 兴源环境 ・ 尔康制药 ・ 佳沃食品
Source: Eastmoney · This page shows public filing data only, not investment advice. · Browse all companies